1—Phenethylbiguanide—an Orally Administered Hypoglycemic Agent

REFERENCES

• Ungar, G., Freedman, L. and Shapiro, S. L.: Pharmacological studies of a new oral hypoglycemic drug. Proc. Soc. Exper. Biol. & Med. 95: 190, 1957.
   PubMed Web of Science ®Google Scholar
• Pomeranze, J., Fujiy, H. and Mouratoff, G. T.: Clinical report of a new hypoglycemic agent. Ibid.,1 p. 193.
   Google Scholar
• Nelson, N.: A photometric adaptation of the Somogyi method for determination of glucose. J. Biol. Chem. 153: 375, 1944.
   Google Scholar
• Williams, R. H., Tanner, D. C. and Odell, W. D.: Hypoglycemic actions of phenethyl-, amyl- and iso- amylbiguanide. Diabetes 7: 87, 1958.
   PubMed Web of Science ®Google Scholar
• Nielsen, R. L., Swanson, H. E., Tanner, D. C. and Williams, R. H.: Effects on blood sugar of a new potent hypoglycemic compound. A.M.A. Arch. Int. Med. 101: 211, 1958.
   Google Scholar
• Hall, G. H., Crowley, M. F. and Bloom, A.: Oral treatment of diabetes. Brit. M. J. 2: 71, 1958.
   PubMedGoogle Scholar
• Odell, W. D., Tanner, D. C., Steiner, D. F. and Williams, R. H.: Phenethyl-, amyl- and isoamyl-biguanide in the treatment of diabetes mellitus. A.M.A. Arch. Int. Med. 102: 520, 1958.
   Google Scholar
• Krall, L. P., White, P. and Bradley, R. F.: Clinical use of the biguanides and their role in stabilizing juvenile-type diabetes. Diabetes 7: 468, 1958.
   PubMed Web of Science ®Google Scholar
• Krall, L. P. and Bradley, R. F.: Clinical evaluation of formamidinyliminourea, a new biguanide oral blood sugar-lowering compound: Comparison with other hypoglycemic agents. Ann. Int. Med. 50: 586, 1959.
   PubMed Web of Science ®Google Scholar
• Lambert, T. H.: Clinical observations with a new oral hypoglycemic agent (DBI). Clin. Res. 6: 92, 1958.
   Google Scholar
• Lundbaek, K., Nielsen, K. and Rafaelsen, O. J.: The mode of action of oral antidiabetic compounds. Lancet 1: 1036, 1958.
   PubMed Web of Science ®Google Scholar
• Skillman, T. G., Kruger, F. A. and Hamwi, G. J.: Metabolic and endocrine studies with phenethyl-diguanide. Diabetes 8: 274, 1959.
   PubMed Web of Science ®Google Scholar
• Beaser, S.: Therapy of diabetes mellitus with combinations of drugs given orally. New England J. Med. 259:1207, 1958.
   PubMed Web of Science ®Google Scholar
• Wick, A. N. and Larson, E. R.: Studies with phenethyldiguanide, a hypoglycemic agent. Clin. Res. 6: 91, 1958.
   Google Scholar
• Wick, A. N. and Stewart, C. J.: Tissue distribution of administered DBI and its relationship to DBI action. Clin. Res. 7: 111, 1959.
   Google Scholar
• Schmidt, L. H., Hughes, H. B. and Smith, C. C.: On the pharmacology of N1-parAchlorophenyl-N5-isopropylbiguanide (Paludrine). J. Pharmacol. & Exper. Therap. 90: 233, 1947.
   PubMed Web of Science ®Google Scholar
• Bodo, R. and Marks, H. P.: Relation of Synthalin to carbohydrate metabolism. J. Physiol. 65: 83, 1928.
   PubMedGoogle Scholar
• Staub, H. and Küng, O.: Zum Synthalinmechanismus. Klin. Wchnschr. 7:1365, 1928.
   Google Scholar
• Creutzfeldt, W. and Moench, A.: Vergleichende Untersuchungen mit den blutzuckersenkenden Guanidinderivaten Synthalin B und Phenyläthyldiguanid (DBI). (Ein Beitrag zur Frage der sog. AZellgifte.) Endokrinologie 36: 167, 1958.
   PubMedGoogle Scholar
• Hollunger, G.: Guanidines and oxidative phosphorylation. Acta pharmacol. et toxicol., supp. 1, 11: 7, 1955.
   Google Scholar
• Randle, P. J. and Smith, G. H.: Regulation of glucose uptake by muscle. I. The effects of insulin, anaerobiosis, and cell poisons on the uptake of glucose and release of potassium by isolated rat diaphragm. Biochem. J. 70: 490, 1958.
   PubMed Web of Science ®Google Scholar
• Fajans, S. S., Moorhouse, J. A., Doorenbos, H., Louis, L. H. and Conn, J. W.: Metabolic effects of phenethylformamidinyliminourea (DBI) in normal subjects and in diabetic patients. Clin. Res. 6: 252, 1958.
   Google Scholar
• Bergen, S. S., Hilton, J. G. and Norton, W. S.: Effects of phenethylbiguanide on adrenal function and responsiveness as measured by ACTH test. Proc. Soc. Exper. Biol. & Med. 98: 625, 1958.
   PubMed Web of Science ®Google Scholar
• Tyberghein, J. M. and Williams, R. H.: Metabolic effects of phenethyldiguanide: A new hypoglycemic compound. Proc. Soc. Exper. Biol. & Med. 96: 29, 1957.
   PubMed Web of Science ®Google Scholar
• Craig, J. W., Miller, M. and Woodward, H., Jr.: The influence of DBI on the metabolism of lactic acid in diabetic patients. American Diabetes Association, San Francisco, 1958.
   Google Scholar
• Steiner, D. F. and Williams, R. H.: Respiratory inhibition and hypoglycemia by biguanides and decamethylenediguanidine. Biochim. et biophys. acta 30: 329, 1958.
   PubMed Web of Science ®Google Scholar
• Wick, A. N., Larson, E. R. and Serif, G. S.: A site of action of phenethylbiguanide—a hypogly-cemic compound. J. Biol. Chem. 233: 296, 1958.
   PubMed Web of Science ®Google Scholar
• Ungar, G., Psychoyos, S. and Hall, H. A.: Action of phenethylbiguanide, a hypoglycemic agent, on tricarboxylic acid cycle. Metabolism 9: 36, 1960.
   PubMed Web of Science ®Google Scholar
• Butterfield, J., Fry, I. K. and Holling, E.: Effects of insulin, tolbutamide and phenethylbiguanide on peripheral glucose uptake in man. Diabetes 7: 449, 1958.
   PubMed Web of Science ®Google Scholar
• Tranquada, R., Kleeman, C. and Brown, J.: The acute effects of DBI on human hepatic intermediary metabolism. Clin. Res. 7: 110, 1959.
   Google Scholar
• Williams, R. H., Tyberghein, J. M., Hyde, P. M. and Nielsen, R. L.: Studies related to the hypoglycemic action of phenethyldiguanide. Metabolism 6: 311, 1957.
   PubMed Web of Science ®Google Scholar
• Bolinger, R. E., McKee, W. P. and Davis, J. W.: Comparative effects of DBI and insulin on glucose uptake of rat diaphragm. Metabolism 9:30, 1960.
   PubMed Web of Science ®Google Scholar